All eyes on MS drug Tysabri ahead of FDA panel
Reuters - USA
CHICAGO, March 3 (Reuters) - Investors are eagerly awaiting the fate of Biogen Idec's(BIIB.O: Quote, Profile, Research) Tysabri, a treatment for multiple ...
See all stories on this topic

Options Update: News From Starbucks, Intel, Google, and Elan
Schaeffers Research - Cincinnati,Ohio,USA
... published in the New England Journal of Medicine reported that Elan's (ELN: sentiment, chart, options) multiple sclerosis (MS) drug, Tysabri, used as a ...
See all stories on this topic